drugset / Trial / NCT00949091
Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindBasic science
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending-doses of TAK-875 in subjects with type 2 diabetes mellitus.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-07
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fasiglifam | Small molecule | 25 mg | Oral |
| Subject | Fasiglifam | Small molecule | 50 mg | Oral |
| Subject | Fasiglifam | Small molecule | 100 mg | Oral |
| Subject | Fasiglifam | Small molecule | 200 mg | Oral |
| Subject | Fasiglifam | Small molecule | 400 mg | Oral |